Rempart Asset Management Inc. Raises Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Rempart Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 2.5% during the 2nd quarter, Holdings Channel.com reports. The firm owned 63,786 shares of the medical instruments supplier’s stock after acquiring an additional 1,565 shares during the period. Becton, Dickinson and accounts for approximately 3.7% of Rempart Asset Management Inc.’s portfolio, making the stock its 13th biggest position. Rempart Asset Management Inc.’s holdings in Becton, Dickinson and were worth $15,725,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Livforsakringsbolaget Skandia Omsesidigt boosted its stake in Becton, Dickinson and by 16.3% during the 1st quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 2,860 shares of the medical instruments supplier’s stock worth $742,000 after purchasing an additional 400 shares during the period. Offit Capital Advisors LLC increased its position in shares of Becton, Dickinson and by 1.4% in the first quarter. Offit Capital Advisors LLC now owns 5,269 shares of the medical instruments supplier’s stock valued at $1,402,000 after buying an additional 75 shares in the last quarter. Rehmann Capital Advisory Group raised its position in shares of Becton, Dickinson and by 10.5% during the 1st quarter. Rehmann Capital Advisory Group now owns 1,929 shares of the medical instruments supplier’s stock worth $513,000 after purchasing an additional 184 shares during the last quarter. Insight Advisors LLC PA acquired a new stake in Becton, Dickinson and during the 1st quarter valued at $421,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Becton, Dickinson and by 34.7% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 42,590 shares of the medical instruments supplier’s stock worth $11,226,000 after buying an additional 10,983 shares in the last quarter. Institutional investors own 86.58% of the company’s stock.

Several equities research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of Becton, Dickinson and from $265.00 to $255.00 in a research note on Thursday, May 5th. StockNews.com upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a report on Friday, June 24th. Wells Fargo & Company raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price on the stock in a research report on Friday, June 24th. Finally, Morgan Stanley boosted their target price on shares of Becton, Dickinson and from $293.00 to $295.00 and gave the company an “overweight” rating in a report on Monday, April 11th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $279.17.

BDX traded up $2.14 during trading on Friday, reaching $248.67. The stock had a trading volume of 19,206 shares, compared to its average volume of 1,273,237. The stock has a 50 day moving average of $249.86 and a two-hundred day moving average of $258.18. The company has a quick ratio of 1.04, a current ratio of 1.52 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $70.89 billion, a price-to-earnings ratio of 38.88, a price-to-earnings-growth ratio of 3.39 and a beta of 0.64. Becton, Dickinson and Company has a 1-year low of $231.46 and a 1-year high of $280.62.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The medical instruments supplier reported $3.18 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.20. The business had revenue of $5.01 billion during the quarter, compared to analyst estimates of $4.78 billion. Becton, Dickinson and had a return on equity of 14.91% and a net margin of 9.59%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.19 earnings per share. On average, research analysts forecast that Becton, Dickinson and Company will post 11.2 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 30th. Stockholders of record on Thursday, June 9th were paid a $0.87 dividend. The ex-dividend date of this dividend was Wednesday, June 8th. This represents a $3.48 annualized dividend and a dividend yield of 1.40%. Becton, Dickinson and’s dividend payout ratio is currently 54.89%.

In related news, VP Thomas J. Spoerel sold 443 shares of the firm’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $260.00, for a total value of $115,180.00. Following the transaction, the vice president now directly owns 1,058 shares in the company, valued at approximately $275,080. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Hickey sold 475 shares of the business’s stock in a transaction on Friday, May 6th. The stock was sold at an average price of $256.00, for a total transaction of $121,600.00. Following the transaction, the executive vice president now directly owns 3,806 shares in the company, valued at approximately $974,336. The disclosure for this sale can be found here. 0.50% of the stock is owned by insiders.

Becton, Dickinson and Company Profile (Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Read More

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXGet Rating).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.